Evidence map›Paper›PMID 38948812›Full record

ArticlebioRxiv : the preprint server for biology2024

Cell of origin alters myeloid-mediated immunosuppression in lung adenocarcinoma.

Minxiao Yang, Noah Shulkin, Edgar Gonzalez, Jonathan Castillo, Chunli Yan, Keqiang Zhang, Leonidas Arvanitis, Zea Borok, W Dean Wallace, Dan Raz and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Minxiao YangDepartment of Integrative Translational Sciences, Beckman Research Institute, City of Hope, Duarte, CA USA 91010.
Noah ShulkinDepartment of Integrative Translational Sciences, Beckman Research Institute, City of Hope, Duarte, CA USA 91010.
Edgar GonzalezDepartment of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA USA 90089.
Jonathan CastilloDepartment of Integrative Translational Sciences, Beckman Research Institute, City of Hope, Duarte, CA USA 91010.
Chunli YanDepartment of Surgery, University of Southern California, Los Angeles, CA USA 90089.
Keqiang ZhangDivision of Thoracic Surgery, Department of Surgery, City of Hope National Medical Center, City of Hope, Duarte, CA USA 91010.
Leonidas ArvanitisDepartment of Pathology, City of Hope National Medical Center, City of Hope, Duarte, CA USA 91010.ORCID 0000-0002-4744-8350
Zea BorokDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA USA 92093.
W Dean WallaceDepartment of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA USA 90089.
Dan RazDivision of Thoracic Surgery, Department of Surgery, City of Hope National Medical Center, City of Hope, Duarte, CA USA 91010.
Evanthia T Roussos TorresDepartment of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA USA 90089.
Crystal N MarconettDepartment of Integrative Translational Sciences, Beckman Research Institute, City of Hope, Duarte, CA USA 91010.ORCID 0000-0002-8463-7126

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Beyond the Barrier: Alveolar Epithelial Cell Biology in Health and DiseaseR35HL135747 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BOROK, ZEA · 2017 to 2023
$6.8M
Targeting myeloid suppression to enhance anti-tumor immunity in breast cancerR01CA283169 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Evanthia Theodosiou Roussos Torres · 2023 to 2026
$2.2M
Elucidating the Cellular Origins of lung adenocarcinomaR01CA262258 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Crystal Nicole Marconett · 2023 to 2026
$1.4M
NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA262258NCI NIH HHS R01 CA283169NHLBI NIH HHS R35 HL135747
6 · The paper itself

Abstract

Solid carcinomas are often highly heterogenous cancers, arising from multiple epithelial cells of origin. Yet, how the cell of origin influences the response of the tumor microenvironment is poorly understood. Lung adenocarcinoma (LUAD) arises in the distal alveolar epithelium which is populated primarily by alveolar epithelial type I (AT1) and type II (AT2) cells. It has been previously reported that

Indexed as

Myeloid-derived suppressor cellsSingle nucleus RNA sequencingTumor-associated macrophagesTumor immune microenvironment

Identifiers

PMID38948812
PMCPMC11213232

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.